Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR2 | O15552 | 3/20 | 0.38 |
| ▸ | BRD4 | O60885 | 9/20 | 0.38 |
| ▸ | BRD2 | P25440 | 5/20 | 0.38 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.38 |
| ▸ | FFAR1 | O14842 | 3/20 | 0.37 |
| ▸ | BRD3 | Q15059 | 4/20 | 0.36 |
| ▸ | EP300 | Q09472 | 1/20 | 0.36 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.35 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.35 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.35 |
| ▸ | ERN1 | O75460 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2409475 | 1.00 | FFAR2 (0.38) | FFAR2BRD4BRD2CREBBPFFAR1 | |
| SCHEMBL2417204 | 0.87 | BRD4 (0.38) | FFAR2BRD4BRD2CREBBPFFAR1 | |
| SCHEMBL2417206 | 0.87 | BRD4 (0.38) | FFAR2BRD4BRD2CREBBPFFAR1 | |
| SCHEMBL2413371 | 0.84 | ERN1 (0.38) | BRD4BRD2CREBBPFFAR1EP300 | |
| SCHEMBL2412056 | 0.84 | BRD4 (0.32) | BRD4 | |
| SCHEMBL2413372 | 0.84 | ERN1 (0.38) | BRD4BRD2CREBBPFFAR1EP300 | |
| SCHEMBL2412061 | 0.84 | BRD4 (0.32) | BRD4 | |
| SCHEMBL2415825 | 0.83 | BRD4 (0.46) | FFAR2BRD4BRD2CREBBPFFAR1 | |
| SCHEMBL2415822 | 0.83 | BRD4 (0.46) | FFAR2BRD4BRD2CREBBPFFAR1 | |
| SCHEMBL2413089 | 0.82 | FFAR2 (0.38) | FFAR2BRD4BRD2CREBBPFFAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8013010-B2 | 5-thioxylopyranose compounds | LABORATOIRES FOURNIER S.A. (FR) | 2011-09-06 | — | — | US | disclosed |
| US-20090186840-A1 | 5-Thioxylopyranose Compounds | LABORATOIRES FOURNIER S.A (FR) | 2009-07-23 | — | — | US | disclosed |
| EP-2066681-A1 | NEW DERIVATIVES OF 5-THIOXILOPYRANOSE | LABORATOIRES FOURNIER SA (FR) | 2009-06-10 | — | — | EP | disclosed |
| WO-2008037923-A1 | NEW DERIVATIVES OF 5-THIOXILOPYRANOSE | LABORATOIRES FOURNIER S.A. (FR) | 2008-04-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090186840-A1 | 5-Thioxylopyranose Compounds | TPMT, PNPO, CYP3A5 | FFAR2 4289/4885BRD4 4110/4885BRD2 4720/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.